T-cell immunoglobulin mucin molecule-3, transformation growth factor β, and chemokine-12 and the prognostic status of diffuse large B-cell lymphoma

Table 3 Univariate analysis of factors affecting patient outcomes, n (%)

Factors		n	Three-year progression-free survival	χ2 value	P value
Sex	Male	53	40 (75.47)	3.784	0.052
	Female	44	25 (56.82)
Age (yr)	≥ 50	54	37 (68.52)	0.125	0.723
	< 50	43	28 (65.12)
Bone marrow infiltration	Presence	48	45 (93.75)	30.733	0.000
	Absence	49	20 (40.82)
B symptom	Presence	50	31 (62.00)	1.172	0.279
	Absence	47	34 (72.34)
Clinical stages	I-II stage	41	10 (24.39)	58.355	0.000
	III-IV stage	56	55 (98.21)
ECOG grade	0-1 points	54	34 (62.96)	0.903	0.342
	≥ 2 points	43	31 (72.09)
IPI grade	Low-risk	64	33 (51.56)	20.307	0.000
	Medium-high risk	33	32 (96.97)
Tim-3 expression	Positive	73	60 (82.19)	30.760	0.000
	Negative	24	5 (20.83)
TGF-β expression	Positive	51	49 (96.08)	41.105	0.000
	Negative	46	16 (34.78)
CXCL12 expression	Positive	82	60 (73.17)	9.103	0.003
	Negative	15	5 (33.33)

ECOG: Eastern Cooperative Oncology Group; IPI: International Prognostic Index; Tim-3: T-cell immunoglobulin mucin molecule-3; TGF-β: Transforming growth factor β; CXCL12: Chemokine 12.